Related Experiment Video
Updated: Oct 18, 2025

12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.6K
Tumor mutational burden and immunotherapy in gliomas
Mythili Merchant1, Alice Ranjan1, Ying Pang1
1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Trends in Cancer
|September 28, 2021
Abstract
None:
Tumor mutational burden (TMB) is an emerging biomarker for the prediction of immunotherapy success in solid tumors. Gliomas, however, do not demonstrate a correlation between TMB and immunotherapy efficacy. Here, we discuss the potential factors influencing this discordance, focusing on the impact of neoantigen immunogenicity, clonality, expression, and presentation.

